FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma.
FDA Grants Fast Track Designation to ITM-11 for Gastroenteropancreatic Neuroendocrine Tumors
The FDA has granted a fast track designation to 177Lu-edotreotide for use as a potential therapeutic option in patients with gastroenteropancreatic neuroendocrine tumors.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512